AR42

TargetMol
Product Code: TAR-T6392
Supplier: TargetMol
CodeSizePrice
TAR-T6392-1mg1mg£100.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-5mg5mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-10mg10mg£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-25mg25mg£332.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-50mg50mg£542.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-100mg100mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6392-200mg200mg£870.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AR-42 is an HDAC inhibitor (IC50: 30 nM).
CAS:
935881-37-1
Formula:
C18H20N2O3
Molecular Weight:
312.36
Pathway:
Chromatin/Epigenetic; DNA Damage/DNA Repair
Purity:
0.9946
SMILES:
CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1
Target:
HDAC

References

Zhu Y, Yuan T, Zhang Y, et al. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma. Drug Design, Development and Therapy. 2019, 13: 4321 Zhang M, et al. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition. Oncotarget. 2016 Apr 19;7(16):22285-94. Chen CS, et al. J Biol Chem, 2005, 280(46), 38879-38887. Kulp SK, et al. Clin Cancer Res, 2006, 12(17), 5199-5206. Chen CS, et al. Cancer Res, 2007, 67(11), 5318-5327. Su L, Wang S, Yuan T, et al. Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42[J]. Journal of Cancer. 2020, 11(2): 364-373. Lu Q, et al. J Med Chem, 2005, 48(17), 5530-5535. Su L, Wang S, Yuan T, et al. Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42. Journal of Cancer. 2020, 11(2): 364-373. Zhu Y, Yuan T, Zhang Y, et al. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma. Drug Design, Development and Therapy. 2019, 13: 4321 Sargeant AM, et al. Cancer Res, 2008, 68(10), 31999-42009. Zhu Y, Yuan T, Zhang Y, et al. AR-42:A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma. Drug Design, Development and Therapy. 2019, 13: 4321.